Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Entamoeba histolytica | hexokinase 1 | 0.0614 | 1 | 0.5 |
Onchocerca volvulus | 0.0614 | 1 | 1 | |
Trypanosoma cruzi | hexokinase, putative | 0.0614 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.0614 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0614 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0614 | 1 | 0.5 |
Schistosoma mansoni | hexokinase | 0.0614 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0614 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0614 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0614 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.0614 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0614 | 1 | 0.5 |
Trypanosoma cruzi | hexokinase, putative | 0.0614 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0614 | 1 | 0.5 |
Echinococcus granulosus | hexokinase type 2 | 0.0614 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0614 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0419 | 0.1468 | 0.1468 |
Echinococcus multilocularis | hexokinase | 0.0614 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0614 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0614 | 1 | 0.5 |
Brugia malayi | Hexokinase family protein | 0.0614 | 1 | 1 |
Trypanosoma brucei | hexokinase | 0.0614 | 1 | 0.5 |
Onchocerca volvulus | 0.0614 | 1 | 1 | |
Echinococcus multilocularis | hexokinase type 2 | 0.0614 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0614 | 1 | 1 |
Plasmodium falciparum | hexokinase | 0.0614 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0614 | 1 | 1 |
Echinococcus granulosus | hexokinase | 0.0614 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.0614 | 1 | 0.5 |
Onchocerca volvulus | 0.0614 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 152 nM | Ability to inhibit the growth of leukemia L1210 cells in vitro. | ChEMBL. | 3625706 |
IC50 (functional) | = 152 nM | Ability to inhibit the growth of leukemia L1210 cells in vitro. | ChEMBL. | 3625706 |
IC50 (functional) | = 270 nM | Ability to inhibit the growth of human colon tumor HCT-8 cells in vitro. | ChEMBL. | 3625706 |
IC50 (functional) | = 270 nM | Ability to inhibit the growth of human colon tumor HCT-8 cells in vitro. | ChEMBL. | 3625706 |
ILS max (functional) | Percent increase in life span of the drug treated tumor bearing animals vs nontreated tumor bearing controls was determined against P388/ADR cells;NA= not active | ChEMBL. | 3625706 | |
ILS max (functional) | 0 | Percent increase in life span of the drug treated tumor bearing animals vs nontreated tumor bearing controls was determined against P388/ADR cells;NA= not active | ChEMBL. | 3625706 |
ILS max (functional) | = 58 | Percent increase in life span of the drug treated tumor bearing animals vs nontreated tumor bearing controls was determined against LL (Lewis lung carcinoma model) cells;NA= not active | ChEMBL. | 3625706 |
ILS max (functional) | = 105 | Percent increase in life span of the drug-treated tumor-bearing animals vs nontreated tumor-bearing controls with P388 leukemia cells. | ChEMBL. | 3625706 |
Log K (binding) | = 6.72 | Binding constant for DNA by ethidium bromide displacement | ChEMBL. | 3625706 |
OD (functional) | = 8.9 | Optimal dose required to inhibit the P388 intraperitoneal administration. | ChEMBL. | 3625706 |
OD (functional) | = 8.9 | Optimal dose required to inhibit the LL (Lewis lung carcinoma model) cells in vivo administered intraperitoneally;NA= not active | ChEMBL. | 3625706 |
OD (functional) | = 13.3 | Optimal dose required to inhibit the P388/ADR cells in vivo after intraperitoneal administration. | ChEMBL. | 3625706 |
Rm | = 0.78 | Lipophilicity (Rm). | ChEMBL. | 3625706 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Mus musculus | ChEMBL23 | 3625706 | |
Homo sapiens | ChEMBL23 | 3625706 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.